Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.Novocure (NASDAQ: NVCR) and its international partner Zai Lab (NASDAQ: ZLAB) announced successful top-line results from the Panova-3 study on Dec. 2, 2024. In a nutshell, it showed that the company's electric field-generating devices can improve pancreatic cancer patients' odds of survival. Uptake could be significant because the relatively benign device produces nearly zero side effects.From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned approval to treat lung cancer patients in October.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool